跳至主要内容
临床试验/NCT01710670
NCT01710670已完成1 期

A Double-blind, Randomized, Placebo-controlled, Three-way Crossover Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects.

UCB Pharma SA0 个研究点目标入组 18 人开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
UCB Pharma SA
入组人数
18
主要终点
Adaptive tracking from 60 minutes Pre-Dose up to 10 hours Post-Dose

研究概览

简要总结

To evaluate if Brivaracetam (BRV) influences the psychomotor and cognitive impairing effects of Ethanol

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male volunteers with the age between 18 and 55 years old

排除标准

  • Subject has participated or is participating in any other clinical studies of investigational drug or another investigational medical product within the last 3 months or has participated in 4 or more Investigational Medicinal Product (IMP) studies within 1 year prior to screening
  • Subject is not healthy (eg, taking any drug treatments except use of Paracetamol, excessive amount of alcohol, cigarettes, caffeine consumption, having a positive drug / alcohol abuse, having abnormal safety parameters)
  • Subject has not been vaccinated for hepatitis
  • Subjects has consumed any grapefruits, grapefruits juice, grapefruit-containing products or star fruit within 14 days prior to dosing or not able to refrain from these products during the study
  • Subject has Ethanol intolerance
  • Subject has a known hypersensitivity to any components of the Investigational Medicinal Product (IMP)
  • Subject has made a blood donation or a comparable blood loss (500 ml) within the last 3 months prior to screening
  • subject is an employee of the investigator or study center or subject is a first line family member of an employee working in the respective study center or of the investigator

研究组 & 干预措施

Ethanol + Brivaracetam

Experimental

Treatment A: Ethanol + Brivaracetam

干预措施: Brivaracetam (Drug)

Ethanol + Brivaracetam

Experimental

Treatment A: Ethanol + Brivaracetam

干预措施: Ethanol (Other)

Ethanol Placebo + Brivaracetam

Experimental

Treatment B: Ethanol Placebo + Brivaracetam

干预措施: Brivaracetam (Drug)

Ethanol Placebo + Brivaracetam

Experimental

Treatment B: Ethanol Placebo + Brivaracetam

干预措施: Ethanol Placebo (Other)

Ethanol + Brivaracetam Placebo

Experimental

Treatment C: Ethanol + Brivaracetam Placebo

干预措施: Ethanol (Other)

Ethanol + Brivaracetam Placebo

Experimental

Treatment C: Ethanol + Brivaracetam Placebo

干预措施: Brivaracetam Placebo (Other)

结局指标

主要结局

Adaptive tracking from 60 minutes Pre-Dose up to 10 hours Post-Dose

时间窗: From 60 minutes Pre-Dose up to 10 hours Post-Dose

Performance will be scored after a fixed period of 3.5 minutes and reflected visuo motor control and vigilance. The average performance scores will be used in the analysis.

Visual Analog Scales for Alertness From 60 minutes Pre-Dose up to 10 hours Post-Dose

时间窗: From 60 minutes Pre-Dose up to 10 hours Post-Dose

Visual Analog Scales according to Bond and Lader

Visual Analog Scales for Calmness From 60 minutes Pre-Dose up to 10 hours Post-Dose

时间窗: From 60 minutes Pre-Dose up to 10 hours Post-Dose

Visual Analog Scales according to Bond and Lader

Saccadic Eye Movements from 60 minutes Pre-Dose up to 10 hours Post-Dose

时间窗: From 60 minutes Pre-Dose up to 10 hours Post-Dose

Average values of Latency (reaction time), Saccadic Peak Velocity, and Inaccuracy (difference between stimulus angle and corresponding saccade in percentages) will be calculated for all artifact-free saccades.

Body sway from 60 minutes Pre-Dose up to 10 hours Post-Dose

时间窗: From 60 minutes Pre-Dose up to 10 hours Post-Dose

The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. (antero-posterior sway in mm / 2 minutes)

Visual Verbal Learning Test from 1.5 hours Post-Dose up to 6 hours Post-Dose

时间窗: From 1.5 hours Post-Dose up to 6 hours Post-Dose

Immediate recall, immediate recognition, delayed recall, and delayed recognition to evaluate memory

Smooth pursuit eye movements from 60 minutes Pre-Dose up to 10 hours Post-Dose

时间窗: From 60 minutes Pre-Dose up to 10 hours Post-Dose

The time during which the eyes are in smooth pursuit of the target will be calculated for each frequency and expressed as a percentage of stimulus duration. The average percentage of smooth pursuit for all stimulus frequencies will be used as a parameter.

Visual Analog Scales for Mood From 60 minutes Pre-Dose up to 10 hours Post-Dose

时间窗: From 60 minutes Pre-Dose up to 10 hours Post-Dose

Visual Analog Scales according to Bond and Lader

Visual Analog Scale for alcohol intoxication From 60 minutes Pre-Dose up to 10 hours Post-Dose

时间窗: From 60 minutes Pre-Dose up to 10 hours Post-Dose

The scale consists of a 10 cm line anchored on the left end by "sober" and on the right end by "drunk." Subjects mark a point on the line that best represents their subjective state corresponding to the condition tested. The result is a distance calculated from the mark on the line.

次要结局

  • Total Ethanol Dose analyzed by a model independent parameter estimate(From - 30 minutes Pre-Dose to 10 hours Post-Dose)
  • The maximum plasma concentration (Cmax)(From Pre-Dose (- 5 minutes) to 36 hours Post-Dose)
  • The area under the plasma concentration-time curve from zero to infinity (AUC)(From Pre-Dose (- 5 minutes) to 36 hours Post-Dose)
  • The area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification [AUC(0-t)](From Pre-Dose (- 5 minutes) to 36 hours Post-Dose)
  • The time to reach the maximum plasma concentration (tmax)(From Pre-Dose (- 5 minutes) to 36 hours Post-Dose)
  • The terminal disposition rate constant (λz) with the respective terminal half-life (t1/2)(From Pre-Dose (- 5 minutes) to 36 hours Post-Dose)
  • Breath Ethanol concentrations(From - 30 minutes Pre-Dose to 10 hours Post-Dose)
  • Serum Ethanol concentrations(From - 30 minutes Pre-Dose to 10 hours Post-Dose)

研究者

发起方
UCB Pharma SA
申办方类型
Industry
责任方
Sponsor

相似试验